Aim: To evaluate and compare the efficacy of combination of ranibizumab or bevacizumab with photodynamic therapy (PDT) in treating choroidal neovascularization (CNV) secondary to age‑related macular degeneration (ARMD) on long‑term follow‑up. Materials and Methods: Of 42 eyes, 18 were treated with bevacizumab (Group A) and 24 with ranibizumab (Group B) in combination with verteporfin PDT. Treatment was initiated after informed consent. Complete ophthalmic examination including optical coherence tomography (OCT) was performed at presentation, 1 month, 3 months, and subsequent follow‑up visits. OCT measures used were lesion thickness (LT) of the CNV, retinal thickness above the lesion (RT), and central macular thickness (CMT). Mean follow‑up period was 33 months (median 18, range 1–84). Additional treatment on follow‑up was left at treating surgeon’s discretion. Results: Visual acuity improved significantly from baseline by 0.3 LogMAR in Group A and 0.26 LogMAR in Group B. LT decreased significantly from 1st month onward and remained significant at all the subsequent visits, in both the groups. CMT and RT showed a decreasing trend in both the groups. No difference was seen in visual acuity (VA), LT, CMT, and RT between Group A and Group B at any of the visits. The mean number of additional anti‑vascular endothelial growth factor injections given postcombination therapy were 1.5 (median 1, range 0–7) injections per eye. Conclusions: PDT in combination with either ranibizumab or bevacizumab was equally effective in preventing vision loss in eyes with wet‑Age-related macular degeneration (ARMD). Such combination also reduces the economic burden of the treatment.

Aim: To evaluate and compare the efficacy of combination of ranibizumab or bevacizumab with photodynamic therapy (PDT) in treating choroidal neovascularization (CNV) secondary to age‑related macular degeneration (ARMD) on long‑term follow‑up. Materials and Methods: Of 42 eyes, 18 were treated ...